Home

14159, L.P.

CIK 1551138 · last filed 2019-02-27

14159, L.P. is a corporate insider who has filed 22 SEC Form 4 insider transactions across 8 companies since 2012. The most recent filing shows the insider exercised options covering $784.0K of INCY on Feb 27, 2019. Across all open-market trades the lifetime net is +$899.9M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $719.2M across reported positions. The firm reports its address in New York, NY. 216 SEC filings were submitted jointly with Baker Brothers Life Sciences LP.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$719.20M

Companies

8

Total Filings

22

Lifetime Open-Market Net

$899.93M

Filer Profile

Reported Address
860 WASHINGTON STREET
3RD FLOOR
NEW YORK, NY 10014
Phone
(212) 339-5600
State of Incorporation
DE
Related Filers
Baker Brothers Life Sciences LP — 216 joint filings, latest 2019-10-03
BAKER BROS. ADVISORS LP — 215 joint filings, latest 2019-10-03
JULIAN BAKER — 215 joint filings, latest 2019-10-03
667, L.P. — 212 joint filings, latest 2019-10-03
FELIX BAKER — 211 joint filings, latest 2019-10-03
Baker Bros. Advisors (GP) LLC — 185 joint filings, latest 2019-10-03
Baker Bros. Investments, L.P. — 82 joint filings, latest 2019-10-03
Baker/Tisch Investments, LP — 82 joint filings, latest 2019-10-03
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
INCY Director 92,042 $126.75 $11.67M $0 6 2019-02-27
Aceragen, Inc. (IDRA) Delisted Director 251,992 $7.22 $1.82M $0 2 2019-01-04
ACAD Director 24,667,110 $28.02 $691.17M $459.53M 2 2018-09-24
GENOMIC HEALTH INC (GHDX) Delisted Director 204,452 — — $223.55M 7 2017-10-03
XOMA Royalty Corp (XOMA) Delisted Director 870,308 $40.17 $34.96M -$92.18M 2 2014-12-10
Seagen Inc. (SGEN) Delisted Director 3,949,073 $228.74 $903.31M $113.02M 1 2013-12-16
BCRX 10%+ Owner 1,642,513 $9.96 $16.36M $50.00M 1 2013-08-02
SYNAGEVA BIOPHARMA CORP (GEVA) Delisted Director 207,820 — — $146.01M 1 2012-07-13

Recent Filings

22 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2019-02-27 INCY Exer (M) +280,000 $784.0K EDGAR
2019-01-04 Aceragen, Inc. (IDRA) Delisted Grant (A) +76,818 $270.4K EDGAR
2018-09-24 ACAD Buy (P) +8,475,432 $158.53M EDGAR
2018-04-02 INCY Grant (A) +4,788 $399.0K EDGAR
2017-10-03 GENOMIC HEALTH INC (GHDX) Delisted Grant (A) +37,320 $1.20M EDGAR
2017-06-01 GENOMIC HEALTH INC (GHDX) Delisted Exer (M) +495,000 $8.97M EDGAR
2017-02-22 INCY Mixed +74,275,474 $0 EDGAR
2016-08-12 ACAD Buy (P) +9,121,210 $301.00M EDGAR
2015-10-05 GENOMIC HEALTH INC (GHDX) Delisted Grant (A) +56,160 $1.20M EDGAR
2015-10-05 INCY Grant (A) +3,612 $398.5K EDGAR
Showing 1–10 of 22
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.